NEMO peptide inhibits the growth of pancreatic ductal adenocarcinoma by blocking NF-κB activation

Zhuonan Zhuang, Hao Li, Harold Lee, Mitzi Aguilar, Takashi Gocho, Huaiqiang Ju, Tomonori Iida, Jianhua Ling, Jie Fu, Min Wu, Yichen Sun, Yu Lu, Paul J. Chiao

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

NF-κB essential modulator (NEMO) binds and regulates IκB kinase (IKK) and is required for NF-κB activation. The NEMO-binding domain peptide (NBDP) of IKK was found to inhibit NF-κB activation and promote apoptosis in cancer cells. Studies have shown that constitutive NF-κB activation, one of the signature molecular alterations in pancreatic ductal adenocarcinoma (PDAC), is a potential therapeutic target. However, preclinical and therapeutic evidence that supports direct targeting of IKK activation in therapy is lacking. The aim of this study was to determine whether the combination of NBDP and gemcitabine would sensitize pancreatic cancer to the gemcitabine. We confirmed that NBDP inhibited NF-κB activation and found that NBDP indeed promoted chemo-sensitivity to gemcitabine in PDAC. NBDP increased PARP and caspase 3 cleavage in the apoptosis pathway, increased apoptosis of PDAC cells, and suppressed PDAC cell growth in vitro. In addition, NBDP combined with gemcitabine significantly decreased levels of NF-κB activity and inhibited the growth of PDAC in vivo in an orthotopic xenograft mouse model. Mechanistic investigations showed that NBDP effectively competed with NEMO/IKKγ for binding to IKKs and thus inhibited IKK and NF-κB activation, down-regulated expression levels of Erk, and decreased PDAC cell growth. Taken together, our current data demonstrate that NBDP sensitizes human pancreatic cancer to gemcitabine by inhibiting the NF-κB pathway. NBDP is a potential adjuvant chemotherapeutic agent for treating pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)44-56
Number of pages13
JournalCancer Letters
Volume411
DOIs
StatePublished - Dec 28 2017

Fingerprint

gemcitabine
Adenocarcinoma
Peptides
Growth
Pancreatic Neoplasms
Apoptosis
Protein Domains
Heterografts
Caspase 3
Phosphotransferases
Therapeutics

Keywords

  • Gemcitabine
  • IKKγ
  • NF-κB
  • Pancreatic cancer
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

NEMO peptide inhibits the growth of pancreatic ductal adenocarcinoma by blocking NF-κB activation. / Zhuang, Zhuonan; Li, Hao; Lee, Harold; Aguilar, Mitzi; Gocho, Takashi; Ju, Huaiqiang; Iida, Tomonori; Ling, Jianhua; Fu, Jie; Wu, Min; Sun, Yichen; Lu, Yu; Chiao, Paul J.

In: Cancer Letters, Vol. 411, 28.12.2017, p. 44-56.

Research output: Contribution to journalArticle

Zhuang, Zhuonan ; Li, Hao ; Lee, Harold ; Aguilar, Mitzi ; Gocho, Takashi ; Ju, Huaiqiang ; Iida, Tomonori ; Ling, Jianhua ; Fu, Jie ; Wu, Min ; Sun, Yichen ; Lu, Yu ; Chiao, Paul J. / NEMO peptide inhibits the growth of pancreatic ductal adenocarcinoma by blocking NF-κB activation. In: Cancer Letters. 2017 ; Vol. 411. pp. 44-56.
@article{eb99bd269d3143aeb2c1d3b09d14ad87,
title = "NEMO peptide inhibits the growth of pancreatic ductal adenocarcinoma by blocking NF-κB activation",
abstract = "NF-κB essential modulator (NEMO) binds and regulates IκB kinase (IKK) and is required for NF-κB activation. The NEMO-binding domain peptide (NBDP) of IKK was found to inhibit NF-κB activation and promote apoptosis in cancer cells. Studies have shown that constitutive NF-κB activation, one of the signature molecular alterations in pancreatic ductal adenocarcinoma (PDAC), is a potential therapeutic target. However, preclinical and therapeutic evidence that supports direct targeting of IKK activation in therapy is lacking. The aim of this study was to determine whether the combination of NBDP and gemcitabine would sensitize pancreatic cancer to the gemcitabine. We confirmed that NBDP inhibited NF-κB activation and found that NBDP indeed promoted chemo-sensitivity to gemcitabine in PDAC. NBDP increased PARP and caspase 3 cleavage in the apoptosis pathway, increased apoptosis of PDAC cells, and suppressed PDAC cell growth in vitro. In addition, NBDP combined with gemcitabine significantly decreased levels of NF-κB activity and inhibited the growth of PDAC in vivo in an orthotopic xenograft mouse model. Mechanistic investigations showed that NBDP effectively competed with NEMO/IKKγ for binding to IKKs and thus inhibited IKK and NF-κB activation, down-regulated expression levels of Erk, and decreased PDAC cell growth. Taken together, our current data demonstrate that NBDP sensitizes human pancreatic cancer to gemcitabine by inhibiting the NF-κB pathway. NBDP is a potential adjuvant chemotherapeutic agent for treating pancreatic cancer.",
keywords = "Gemcitabine, IKKγ, NF-κB, Pancreatic cancer, Targeted therapy",
author = "Zhuonan Zhuang and Hao Li and Harold Lee and Mitzi Aguilar and Takashi Gocho and Huaiqiang Ju and Tomonori Iida and Jianhua Ling and Jie Fu and Min Wu and Yichen Sun and Yu Lu and Chiao, {Paul J.}",
year = "2017",
month = "12",
day = "28",
doi = "10.1016/j.canlet.2017.09.018",
language = "English (US)",
volume = "411",
pages = "44--56",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - NEMO peptide inhibits the growth of pancreatic ductal adenocarcinoma by blocking NF-κB activation

AU - Zhuang, Zhuonan

AU - Li, Hao

AU - Lee, Harold

AU - Aguilar, Mitzi

AU - Gocho, Takashi

AU - Ju, Huaiqiang

AU - Iida, Tomonori

AU - Ling, Jianhua

AU - Fu, Jie

AU - Wu, Min

AU - Sun, Yichen

AU - Lu, Yu

AU - Chiao, Paul J.

PY - 2017/12/28

Y1 - 2017/12/28

N2 - NF-κB essential modulator (NEMO) binds and regulates IκB kinase (IKK) and is required for NF-κB activation. The NEMO-binding domain peptide (NBDP) of IKK was found to inhibit NF-κB activation and promote apoptosis in cancer cells. Studies have shown that constitutive NF-κB activation, one of the signature molecular alterations in pancreatic ductal adenocarcinoma (PDAC), is a potential therapeutic target. However, preclinical and therapeutic evidence that supports direct targeting of IKK activation in therapy is lacking. The aim of this study was to determine whether the combination of NBDP and gemcitabine would sensitize pancreatic cancer to the gemcitabine. We confirmed that NBDP inhibited NF-κB activation and found that NBDP indeed promoted chemo-sensitivity to gemcitabine in PDAC. NBDP increased PARP and caspase 3 cleavage in the apoptosis pathway, increased apoptosis of PDAC cells, and suppressed PDAC cell growth in vitro. In addition, NBDP combined with gemcitabine significantly decreased levels of NF-κB activity and inhibited the growth of PDAC in vivo in an orthotopic xenograft mouse model. Mechanistic investigations showed that NBDP effectively competed with NEMO/IKKγ for binding to IKKs and thus inhibited IKK and NF-κB activation, down-regulated expression levels of Erk, and decreased PDAC cell growth. Taken together, our current data demonstrate that NBDP sensitizes human pancreatic cancer to gemcitabine by inhibiting the NF-κB pathway. NBDP is a potential adjuvant chemotherapeutic agent for treating pancreatic cancer.

AB - NF-κB essential modulator (NEMO) binds and regulates IκB kinase (IKK) and is required for NF-κB activation. The NEMO-binding domain peptide (NBDP) of IKK was found to inhibit NF-κB activation and promote apoptosis in cancer cells. Studies have shown that constitutive NF-κB activation, one of the signature molecular alterations in pancreatic ductal adenocarcinoma (PDAC), is a potential therapeutic target. However, preclinical and therapeutic evidence that supports direct targeting of IKK activation in therapy is lacking. The aim of this study was to determine whether the combination of NBDP and gemcitabine would sensitize pancreatic cancer to the gemcitabine. We confirmed that NBDP inhibited NF-κB activation and found that NBDP indeed promoted chemo-sensitivity to gemcitabine in PDAC. NBDP increased PARP and caspase 3 cleavage in the apoptosis pathway, increased apoptosis of PDAC cells, and suppressed PDAC cell growth in vitro. In addition, NBDP combined with gemcitabine significantly decreased levels of NF-κB activity and inhibited the growth of PDAC in vivo in an orthotopic xenograft mouse model. Mechanistic investigations showed that NBDP effectively competed with NEMO/IKKγ for binding to IKKs and thus inhibited IKK and NF-κB activation, down-regulated expression levels of Erk, and decreased PDAC cell growth. Taken together, our current data demonstrate that NBDP sensitizes human pancreatic cancer to gemcitabine by inhibiting the NF-κB pathway. NBDP is a potential adjuvant chemotherapeutic agent for treating pancreatic cancer.

KW - Gemcitabine

KW - IKKγ

KW - NF-κB

KW - Pancreatic cancer

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85030974603&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030974603&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2017.09.018

DO - 10.1016/j.canlet.2017.09.018

M3 - Article

C2 - 28951128

AN - SCOPUS:85030974603

VL - 411

SP - 44

EP - 56

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

ER -